Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.68 |
| ▸ | F2 | P00734 | 2/20 | 0.56 |
| ▸ | TERT | O14746 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.54 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19069603 | 1.00 | DTYMK (0.68) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL19069699 | 1.00 | DTYMK (0.68) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL16743928 | 1.00 | DTYMK (0.68) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL16508423 | 1.00 | DTYMK (0.68) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL20090644 | 1.00 | DTYMK (0.68) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL20090645 | 1.00 | DTYMK (0.68) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL23476999 | 0.94 | F2 (0.63) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL8612856 | 0.93 | DTYMK (0.74) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL8613042 | 0.93 | DTYMK (0.74) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL17268344 | 0.93 | DTYMK (0.74) | DTYMKF2TERTPOLBENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040234-B2 | Oligonucleotide analogs as therapeutic agents | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | DTYMK 22/4885F2 4766/4885TERT 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.